Gossamer IPO looks to create $1 billion biotech company

plans to pool 6 billion euros ($6.8 billion) of its smaller European warehouse investments in a new company that will ultimately be publicly listed or sold, according to people with knowledge of the... To view the full story, click the title link......»»

The former site head of Bayer's Berkeley campus is taking over as CEO of Menlo Park, California-based Grail Inc., which has raised close to $2 billion to develop a simple blood test aimed at detecting cancer early. Hans Bishop, who led Seattle-ba.....»»

United Technologies Corp said on Monday it expects to secure regulatory approval by the first quarter of 2020 to combine its aerospace business with U.S. contractor Raytheon Co and create a new company worth about $121 billion......»»

Shares of defense contractor Raytheon Co and United Technologies Corp pared gains on Monday after U.S. President Donald Trump said he was a "little concerned" about their $121 billion merger to create a new aero-defense company......»»

United Technologies Corp agreed on Sunday to combine its aerospace business with U.S. contractor Raytheon Co and create a new company worth about $121 billion, in what would be the sector's biggest ever merger......»»

United Technologies Corp agreed on Sunday to combine its aerospace business with U.S. defense contractor Raytheon Co and create a new company worth more than $120 billion, in what would be the industry's biggest ever merger......»»

Newmont Mining shareholders on Thursday approved the company's $10 billion takeover of Goldcorp Inc which is set to create the world's biggest gold producer with assets across the Americas, Africa and Australia......»»

CytoDyn Inc. (OTC: CYDY), a Vancouver, Wash., biotechnology company developing an HIV therapy, announced it has signed a manufacturing agreement with Samsung BioLogics worth $1 billion. Samsung Biologics will manufacture CytoDyn’s drug leronlimab. The.....»»

The chances that your startup will become a billion-dollar company are almost zero. But if you do somehow manage to create a unicorn, the odds are better than 1-in-10 that you or your co-founder attended one school: Stanford......»»

Japanese pharmaceutical company Takeda has made a big breakthrough in its campaign to buy biotech firm Shire -- but its investors are getting worried......»»

Japanese pharmaceutical company Takeda took a fourth try at buying Shire on Friday, less than 24 hours after a potential rival bidder ruled itself out of a tug-of-war for the biotech firm......»»

If customers don't trust you to act in their best interests, they will look for excuses to find a supplier who will. A CEO who can create a culture that spurs customers to rave about the company, instead of raging, can boost its value tremendously......»»

If customers don't trust you to act in their best interests they will look for excuses to find a supplier who will. A CEO who can create a culture that spurs customers to rave about the company, instead of raging can boost its value tremendously......»»

Flickr/B Rosen Seed, a new company with some big names behind it, is about to break into the $38-billion probiotics industry.  They aim to rely on real science to create their product, a probiotic designed to support the vibrant ecosystem.....»»

Ohio-based Marathon Petroleum Corp. (NYSE: MPC) is getting even bigger, buying San Antonio-based refining company Andeavor (NYSE: ANDV) in a deal worth more than $23 billion, according to an April 30 announcement. The combined company's headquart.....»»

Rockville-based BeneVir Biopharm Inc., a biotech specializing in immunotherapy treatments for cancer, has reached a deal to sell to pharmaceutical goliath Janssen Biotech Inc., a Johnson & Johnson company, in a deal worth up to $1.04 billion. Janssen,.....»»

Eli Lilly & Co. will buy the immuno-oncology biotech ARMO Biosciences Inc. for about $1.6 billion in an all-cash deal, the company announced early Thursday. ARMO Biosciences shares surged 77.6% .....»»

Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (.....»»

Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (NA.....»»

A small Peninsula biotech's $1.6 billion buyout by Eli Lilly and Co. would create big Bay Area venture capital winners — including a 50x return for Kleiner Perkins Caufield & Byers — and could turn the cancer immunotherapy investing space white.....»»